IXALTIS expands development of Litoxetine to the USA

IXALTIS expands development of Litoxetine to the USA

Toulouse (31) / Archamps (74), October 16th,2017 – Following the launch of the phase II clinical study of its leading compound Litoxetine IXA-001 in Europe and Canada, Ixaltis announces the acceptance by the Food and Drug Administration of their Investigational New Drug (IND) application.

Vous pouvez télécharger l’intégralité du communiqué de presse en cliquant sur le lien ci-après :

PR2 Ixaltis US IND – ENG – FINAL

START TYPING AND PRESS ENTER TO SEARCH